Traditional centralised manufacturing can cost more than $350,000 per product, explains Boro Dropulić (pictured), Executive Director at Caring Cross, placing these life-saving treatments out of reach for most healthcare systems worldwide.
The bottleneck isn’t scientific; it’s manufacturing, logistical, financial and infrastructural. But a shift toward decentralised, local and in-hospital CAR-T cell therapy production could change that.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.